Research Article
Antibiotic Resistance Profile of Staphylococcus aureus in Cancer Patients at Laquintinie Hospital in Douala, Littoral Region, Cameroon
Table 5
Antibiotic resistance profile of Staphylococcus aureus isolates from cancer and noncancer patients.
| | Antibiotics | Patients, Staphylococcus aureus profile, and statistical analyses | | Cancer + () (%) | Cancer - () (%) | | value |
| | AMX | S | 18 (29.03) | 2 (10.53) | 1.17 | 0.05 | | I | 0 (0.00) | 0 (0.00) | | R | 44 (70.97) | 17 (89.47) |
| | AMC | S | 14 (22.58) | 13 (68.42) | 11.76 | <0.0 01 | | I | 0 (0.00) | 0 (0.00) | | R | 48 (77.42) | 6 (31.58) |
| | FOX | S | 12 (19.35) | 7 (36.84) | 1.14 | 0.06 | | I | 0 (0.00) | 0 (0.00) | | R | 50 (80.65) | 12 (63.16) |
| | CAZ | S | 10 (16.13) | 5 (26.32) | 1.01 | 0.170 | | R | 52 (83.87) | 14 (73.68) |
| | AMK | S | 50 (80.65) | 15 (78.95) | 0.85 | 0.551 | | R | 12 (19.35) | 4 (21.05) |
| | GEN | S | 53 (85.48) | 17 (89.47) | 0.78 | 0.353 | | R | 9 (14.52) | 2 (10.53) |
| | CIP | S | 13 (20.97) | 12 (63.16) | 15.50 | <0.0 01 | | I | 2 (3.23) | 2 (10.53) | | R | 47 (75.81) | 5 (26.32) |
| | OFX | S | 17 (27.42) | 13 (68.42) | 10.64 | <0.0 01 | | I | 2 (3.23) | 0 (0.00) | | R | 45 (69.35) | 6 (31.58) |
| | FUS | S | 17 (27.42) | 9 (47.37) | 0.79 | 0.241 | | I | 1 (1.61) | 0 (0.00) | | R | 44 (70.97) | 10 (53.63) |
| | TET | S | 9 (14.52) | 4 (21.05) | 0.345 | 0.254 | | I | 0 (0.00) | 0 (0.00) | | R | 53 (85.48) | 15 (78.95) |
| | NIT | S | 4 (6.45) | 11 (57.89) | 29.87 | <0.0 01 | | I | 0 (0.00) | 1 (5.26) | | R | 58 (93.55) | 7 (36.84) |
| | COT | S | 28 (45.16) | 8 (42.11) | 0.25 | 0.412 | | R | 34 (54.84) | 11 (57.89) |
| | ERY | S | 9 (14.52) | 2 (10.52) | 1.02 | 0.287 | | R | 53 (85.48) | 17 (89.47) |
|
|
AMX: amoxicillin; AMC: amoxicillin-clavulanic acid; CAZ: ceftazidime; FOX: cefoxitin; AMK: amikacin; GEN: gentamicin; TET: tetracycline; CIP: ciprofloxacin; NIT: nitrofurantoin; OFX: ofloxacin; COT: trimethoprim-sulfamethoxazole; FUS: fusidic acid; ERY: erythromycin; cancer +: cancer patients; cancer -: noncancer patients; S: sensitive; I: intermediate; R: resistant.
|
